NAVBQ (Navidea Biopharmaceuticals) Current Accrued Expense: $3.85 Mil (As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NAVBQ Navidea Biopharmaceuticals Inc NAVBQ
16 GF Score
Price $0.00
View Full Analysis

What is Navidea Biopharmaceuticals Current Accrued Expense?

Navidea Biopharmaceuticals NAVBQ -99.00% 16 Current Accrued Expense is $3.85 Mil as of Sep. 2023. GuruFocus rates NAVBQ with a GF Score™ of 16/100.

Navidea Biopharmaceuticals's Current Accrued Expense for the quarter that ended in Sep. 2023 was $3.85 Mil.

Navidea Biopharmaceuticals's quarterly Current Accrued Expense declined from Mar. 2023 ($4.93 Mil) to Jun. 2023 ($4.16 Mil) and declined from Jun. 2023 ($4.16 Mil) to Sep. 2023 ($3.85 Mil).

Navidea Biopharmaceuticals's annual Current Accrued Expense increased from Dec. 2020 ($1.73 Mil) to Dec. 2021 ($1.91 Mil) and increased from Dec. 2021 ($1.91 Mil) to Dec. 2022 ($5.67 Mil).

Navidea Biopharmaceuticals Current Accrued Expense Related Terms

Navidea Biopharmaceuticals Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Navidea Biopharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Navidea Biopharmaceuticals Current Accrued Expense Chart

Navidea Biopharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.87 1.21 1.73 1.91 5.67

Navidea Biopharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.87 5.67 4.93 4.16 3.85
NAVBQ
16GF Score
Navidea Biopharmaceuticals Inc NAVBQ
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Navidea Biopharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $3.85 Mil mean?
Navidea Biopharmaceuticals (NAVBQ) has a Current Accrued Expense of $3.85 Mil as of Sep. 2023. Current Accrued Expense records the total amount of accrued expenses. View historical data on Navidea Biopharmaceuticals and its competitors.
Is Navidea Biopharmaceuticals' Current Accrued Expense too high?
Navidea Biopharmaceuticals' current Current Accrued Expense is $3.85 Mil. Overall, Navidea Biopharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Navidea Biopharmaceuticals' Current Accrued Expense compare to PKBO and RSPI?
Navidea Biopharmaceuticals' Current Accrued Expense of $3.85 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Navidea Biopharmaceuticals and its competitors. Navidea Biopharmaceuticals's current Current Accrued Expense is $3.85 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Navidea Biopharmaceuticals stock overvalued right now?
Navidea Biopharmaceuticals (NAVBQ) has a current Current Accrued Expense of $3.85 Mil. The current Current Accrued Expense is $3.85 Mil. Navidea Biopharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Navidea Biopharmaceuticals (NAVBQ), the current Current Accrued Expense is $3.85 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Navidea Biopharmaceuticals Business Description

Address 4995 Bradenton Avenue, Suite 240, Dublin, OH, USA, 43017-3552
Navidea Biopharmaceuticals Inc is a biotechnology company specializied in precision medicine. Its products, precision immunodiagnostic agents and immunotherapeutic products are designed to assist in the identification of undetected diseases and to improve targeted treatment. The company's platform, known as Manocept technology, aims to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. One of the company's products is Lymphoseek, a radioactive diagnostic agent indicated to locate lymph nodes.
16GF Score

Get the complete analysis for NAVBQ

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price